Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034243088> ?p ?o ?g. }
- W3034243088 endingPage "1970" @default.
- W3034243088 startingPage "1957" @default.
- W3034243088 abstract "Approximately 89% of patients with Parkinson’s disease (PD) suffer from dysarthria. Lee Silverman Voice Treatment (LSVT), a behavioral therapy, aims to improve speech and voice functions. The objective was to assess the effectiveness of LSVT compared with other/no speech interventions for dysarthria in patients with PD. Electronic databases, including PubMed, Embase and the Cochrane Library, were searched. The publication date of all included studies was before 6 March 2020. Only randomized controlled trials (RCTs) that evaluated the LSVT intervention compared with other/no speech intervention were considered. The data obtained from the included studies were described and the mean differences were calculated. Eight RCTs were included in this meta‐analysis comparing LSVT with other/no speech interventions. In the comparison of LSVT versus no intervention, vocal intensity for sustained ‘Ah’ phonation, reading the ‘Rainbow passage’, monologue and describing a picture increased by 8.87, 4.34, 3.25 and 3.31 dB, respectively, after 1 month of therapy. Compared with the respiratory therapy group, the LSVT group also showed significant improvement in vocal intensity for sustained ‘Ah’ phonation, reading the ‘Rainbow passage’ and monologue immediately after treatment (13.39, 6.66 and 3.19 dB). Positive improvement still existed after 24 months. There was no difference in the therapeutic effect between face‐to‐face and online LSVT. The effectiveness of LSVT for dysarthria in patients with PD was verified in these trials. However, future RCTs with sufficient participants are essential to evaluate the effectiveness of LSVT for dysarthria." @default.
- W3034243088 created "2020-06-19" @default.
- W3034243088 creator A5008321198 @default.
- W3034243088 creator A5014553834 @default.
- W3034243088 creator A5018822768 @default.
- W3034243088 creator A5024136480 @default.
- W3034243088 creator A5025599523 @default.
- W3034243088 creator A5028707927 @default.
- W3034243088 creator A5031789036 @default.
- W3034243088 creator A5036703846 @default.
- W3034243088 creator A5050465904 @default.
- W3034243088 creator A5055512367 @default.
- W3034243088 creator A5058632240 @default.
- W3034243088 creator A5081858883 @default.
- W3034243088 creator A5083373577 @default.
- W3034243088 creator A5087272196 @default.
- W3034243088 creator A5089057215 @default.
- W3034243088 date "2020-08-12" @default.
- W3034243088 modified "2023-10-10" @default.
- W3034243088 title "Lee Silverman Voice Treatment for dysarthria in patients with Parkinson’s disease: a systematic review and meta‐analysis" @default.
- W3034243088 cites W1557807843 @default.
- W3034243088 cites W1572276522 @default.
- W3034243088 cites W1790574068 @default.
- W3034243088 cites W1801340045 @default.
- W3034243088 cites W1900154594 @default.
- W3034243088 cites W1932336117 @default.
- W3034243088 cites W1968573968 @default.
- W3034243088 cites W1969285471 @default.
- W3034243088 cites W1976357112 @default.
- W3034243088 cites W1978820543 @default.
- W3034243088 cites W1978866226 @default.
- W3034243088 cites W1979721417 @default.
- W3034243088 cites W1987743150 @default.
- W3034243088 cites W1987962351 @default.
- W3034243088 cites W1995516199 @default.
- W3034243088 cites W1998034600 @default.
- W3034243088 cites W1998362980 @default.
- W3034243088 cites W2001335932 @default.
- W3034243088 cites W2004528618 @default.
- W3034243088 cites W2011607280 @default.
- W3034243088 cites W2022357919 @default.
- W3034243088 cites W2022554656 @default.
- W3034243088 cites W2025263798 @default.
- W3034243088 cites W2030223911 @default.
- W3034243088 cites W2034476529 @default.
- W3034243088 cites W2043039711 @default.
- W3034243088 cites W2044110840 @default.
- W3034243088 cites W2049581078 @default.
- W3034243088 cites W2052410075 @default.
- W3034243088 cites W2058840541 @default.
- W3034243088 cites W2061588984 @default.
- W3034243088 cites W2065097374 @default.
- W3034243088 cites W2067586272 @default.
- W3034243088 cites W2069204970 @default.
- W3034243088 cites W2075271794 @default.
- W3034243088 cites W2076895998 @default.
- W3034243088 cites W2081070229 @default.
- W3034243088 cites W2083437446 @default.
- W3034243088 cites W2083489522 @default.
- W3034243088 cites W2103082244 @default.
- W3034243088 cites W2104157655 @default.
- W3034243088 cites W2119820106 @default.
- W3034243088 cites W2122569913 @default.
- W3034243088 cites W2122835755 @default.
- W3034243088 cites W2123432286 @default.
- W3034243088 cites W2123874025 @default.
- W3034243088 cites W2144708914 @default.
- W3034243088 cites W2147888511 @default.
- W3034243088 cites W2151869125 @default.
- W3034243088 cites W2160180857 @default.
- W3034243088 cites W2170612827 @default.
- W3034243088 cites W2308354284 @default.
- W3034243088 cites W2346483403 @default.
- W3034243088 cites W2570163329 @default.
- W3034243088 cites W2726253519 @default.
- W3034243088 cites W2753936444 @default.
- W3034243088 cites W2764246309 @default.
- W3034243088 cites W2782921375 @default.
- W3034243088 cites W2784764181 @default.
- W3034243088 cites W2785233760 @default.
- W3034243088 cites W2791833465 @default.
- W3034243088 cites W2889914444 @default.
- W3034243088 cites W2891914535 @default.
- W3034243088 cites W2893508126 @default.
- W3034243088 cites W2897715929 @default.
- W3034243088 cites W2904898407 @default.
- W3034243088 cites W2907002365 @default.
- W3034243088 cites W2907076151 @default.
- W3034243088 cites W2912830999 @default.
- W3034243088 cites W2944022464 @default.
- W3034243088 cites W2975193718 @default.
- W3034243088 cites W2997929009 @default.
- W3034243088 cites W3009965961 @default.
- W3034243088 cites W3011380217 @default.
- W3034243088 cites W3012537127 @default.
- W3034243088 doi "https://doi.org/10.1111/ene.14399" @default.
- W3034243088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32539227" @default.
- W3034243088 hasPublicationYear "2020" @default.